CEO Renée Aguiar-Lucander credits successful debt refinanci...

CEO Renée Aguiar-Lucander credits successful debt refinancing, a strengthened US leadership team, and TARPEYO's US approval for the company's performance in 2023. Foresees potential for more growth and profitability in the rare disease space in 2024.

Press Release: Calliditas Therapeutics Provides Business Update Ahead of JP Morgan Conference

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

1765 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

3154Followers

0Following

7905Visitors